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Abstract
Recombinant adeno-associated viral (rAAV) vectors can support long-term transgene expression in quiescent tissues.
Intramuscular (IM) administration of a single-stranded AAV vector (ssAAV) in the nonhuman primate (NHP) results in a peak
protein level at 2–3 months, followed by a decrease over several months before reaching a steady-state. To investigate
transgene expression and vector genome persistence, we previously demonstrated that rAAV vector genomes associate
with histones and form a chromatin structure in NHP skeletal muscle more than one year after injection. In the mammalian
nucleus, chromatin remodeling via epigenetic modifications plays key role in transcriptional regulation. Among those, CpG
hyper-methylation of promoters is a known hallmark of gene silencing. To assess the involvement of DNA methylation on
the transgene expression, we injected NHP via the IM or the intravenous (IV) route with a recombinant ssAAV2/1 vector. The
expression cassette contains the transgene under the transcriptional control of the constitutive Rous Sarcoma Virus
promoter (RSVp). Total DNA isolated from NHP muscle and liver biopsies from 1 to 37 months post-injection was treated
with sodium bisulfite and subsequently analyzed by pyrosequencing. No significant CpG methylation of the RSVp was
found in rAAV virions or in vector DNA isolated from NHP transduced tissues. Direct de novo DNA methylation appears not
to be involved in repressing transgene expression in NHP after gene transfer mediated by ssAAV vectors. The study
presented here examines host/vector interactions and the impact on transgene expression in a clinically relevant model.
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Introduction
Recombinant Adeno-Associated Virus (rAAV)-mediated gene
transfer can sustain long-term expression of a protein in large
animal models after a single administration in skeletal muscle
[1–4]. After intramuscular (IM) injection of single-stranded AAV
(ssAAV) vectors in nonhuman primates (NHP), a rise in the level of
vector-expressed secreted proteins is seen in the serum during the
first 2–3 months (Phase 1), followed by a progressive decrease
(Phase 2) [1–4]. The protein concentration reaches a steady-state
(Phase 3) 6–8 months post-injection (pi) at half the maximum level.
After IM injection of ssAAV vectors in mouse, the maximal
protein expression is also attained in <10 weeks. Phase 2
reduction seems however less obvious [5–7]. Whereas rAAV
trafficking and double-stranded conversion characterizing Phase 1
were extensively studied [8,9], the mechanism(s) underlying
decreasing protein level in Phase 2 in NHP has not been
elucidated.
Recombinant AAV vector genomes persist mainly as circular
episomes (monomers and high-molecular weight concatemers) in
NHP muscle and liver [4,10,11]. These molecular structures seem
to be more heterogeneous in macaque than in murine liver [10].
Similar to other non-integrating viruses [12,13], we recently
demonstrated that the rAAV episomes assimilate, in NHP skeletal
muscle, into a chromatin-like structure where nucleosomes are
regularly assembled along the viral genome in a pattern similar to
cellular chromatin [4]. Chromatinization may contribute to the
stability of rAAV DNA in quiescent tissues, but could also lead to
epigenetic-mediated modulation of transgene expression. Indeed,
in mammals, chromatin structure accessibility is affected by two
main epigenetic modifications: post-transcriptional modifications
(PTM) of histones [14] and direct DNA methylation on cytosine of
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cooperation to influence transcription levels in a positive or a
negative manner [17].
In mammals, CpG hypermethylation of promoters is known to
be associated with inactivation of gene expression [15,16]. With
regards to gene therapy, CpG methylation has been identified as a
mark of transgene silencing after MLV retroviral vector
transduction [18,19]. DNA methylation was also considered as a
potential cause of transcriptional repression after plasmid-
mediated gene expression [20,21]. Nevertheless, it seems that
histone modifications are more involved in this regulation than
DNA methylation per se [22,23]. Concerning wild-type episomal
viruses, the situation is variable. DNA methylation plays a crucial
role in the Epstein Barr Virus (EBV) lifecycle for example, but is
not involved in gene regulation of other herpes viruses [24]. We
therefore investigated whether rAAV vector genomes are subject
to DNA methylation and partially silenced after gene transfer in
skeletal muscle and liver of a clinically relevant model, the NHP.
Next generation sequencing technologies were recently shown
to be powerful and reproducible methods to quantify CpG
methylation [25–28]. Thus, we performed pyrosequencing
analyses after sodium bisulfite conversion of vector molecules that
were isolated directly from rAAV-transduced NHP tissues. We
quantified the methylation percentage on each CpG of the
constitutive Rous Sarcoma Virus promoter (RSVp). The RSVp
contains a CpG region of intermediate density [29,30], and this
category of promoter has been reported as most sensitive to de novo
DNA methylation [31]. Indeed, several studies have shown that
even low levels of methylation in the RSV long terminal repeat
(LTR) can be sufficient for its transcriptional inactivation [32–34].
In the present study, we established that the CpGs located in the
RSVp are unmethylated in the rAAV vector virion stocks, and
that rAAV genomes are not subject to de novo methylation in NHP
skeletal muscle and liver at early (1 month) to late time points (up
to 37 months). In order to directly correlate the local transgene
expression with the lack of rAAV vector DNA methylation, a
quantitative RT-PCR assay was validated and a dramatically
higher transgenic RNA level was seen in the skeletal muscle
compared to the liver from the same animals. Thus, the majority
of rAAV-derived transgene protein is expressed from the
transduced skeletal muscle. After analyzing the rAAV genome
population and individual rAAV genomes isolated from trans-
duced muscle, our data show that DNA methylation is not
involved in the partial suppression of transgene expression after
ssAAV vector administration in the NHP.
Materials and Methods
Ethics Statement
Experiments were conducted on 3–5 kg captive-bred cynomol-
gus macaques purchased from BioPrim (Bazie `ge, France). Ma-
caques were housed in an enriched environment (toys, fresh fruits
and vegetables) and were monitored daily for health and welfare.
The Institutional Animal Care and Use Committee of the Pays de
Loire (France) approved the protocol (permit number #2006.5).
The research was conducted at the Boisbonne Centre (ONIRIS,
Nantes) under the authorizations #5937C and #005608D
delivered by the Departmental Direction of Veterinary Services
(Loire-Atlantique, France) and in accordance with the recommen-
dations of the Weatherall report: ‘‘The use of nonhuman primates
in research’’.
The experimental protocol was designed in a previous study [2].
In order to avoid any discomfort during and after the experi-
ments, all procedures were carried out after animal sedation with
30 mg/kg of Medetomidine (DomitorH, Pfizer) and 7 mg/kg of
Ketamine (ImalgeneH, Merial). Intramuscular and intravenous
injections of rAAV vectors were classified as mild severity
procedures and skeletal muscle and liver biopsies as moderate
level severity. Surgeries were performed under Isofluorane
anesthesia, monitoring clinical parameters (temperature, blood
pressure, heart rate, respiratory rate…). Pre-operative analgesia
was obtained by intra-cutaneous injection of 0.1 mg/kg of
Morphine and a treatment with a non-steroidal anti-inflammatory
drug (0.1 mg/kg of Meloxicam, MetacamH) was orally adminis-
tered after surgery for 3 days. Special attention was paid to the
health and welfare of animals during the work, and blood samples
were collected regularly to follow biochemical and hematological
parameters.
Mouse experiments were conducted under the agreement
#A44-124 delivered by the Departmental Direction of Veterinary
Services (Loire-Atlantique, France) and in accordance with the
French law concerning experimentations on vertebrate laboratory
animals (De ´cret 87-848, 1987). All animals were handled in
accordance with the Guide for the Care and Use of Laboratory
Animals.
Recombinant AAV vector production and in vivo
administration
The pZA-RSV-LEA29Y-WPRE-pA vector plasmid and the
rAAV2/1 vector virions production were described previously by
Toromanoff et al. [2]. The expression cassette is composed of the
Rous Sarcoma Virus (RSV) promoter that drives the expression of
the immunosuppressive LEA29Y (belataceptH) protein. Five
cynomolgus macaques were injected IM in the tibialis anterior
muscle (Mac 1, Mac 2, and Mac 9) [2] or IV in the right external
saphenous vein (Mac 10 and Mac 11) with rAAV2/1 at a dose of
5.10
12 vector genomes (vg) per kg.
The pAAV-RSV-GFP-pA vector plasmid contains the green
fluorescent protein (GFP) sequence between the RSVp and the
SV40 polyA signal sequences. Ten week-old C57B/6J mice were
injected in the two tibialis anterior muscles with a total dose of
2.8.10
12 vg/kg of single-stranded AAV2/8-RSV-GFP-pA vector.
Animals were sacrificed at 7 days post-injection.
Total DNA and viral DNA extraction
Total DNA was extracted by incubating minced NHP skeletal
muscle or liver biopsies in urea buffer and proteinase K at 56uC
and subsequently purified by a phenol-chloroform organic
extraction. Recombinant AAV viral DNA was recovered using
NucleoSpinH Blood Kit (Macherey Nagel) from 2.10
12 vg of
rAAV2/1-RSV-LEA29Y-WPRE per column according to the
manufacturer instructions.
Quantitative PCR
Primers and TaqMan probes used for the amplification of
vector-specific sequence (LEA29Y) and of endogenous macaque
sequence (macaque e-globin gene), as well as Q-PCR conditions
were previously described by Toromanoff et al. [2].
RNA extraction and quantitative RT-PCR
RNA was isolated from NHP tissues by mechanical shredding
followed by organic extraction using TRI ReagentH (Ambion).
Residual DNA was removed from RNA preparations using the
TURBO DNA-free
TM kit (Ambion). The reverse transcription was
performed using the M-MLV-reverse transcriptase (Invitrogen).
We quantified the transgene-derived mRNA by targeting the
WPRE sequence using primers and Q-PCR conditions described
Absence of rAAV DNA Methylation in NHP
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primers for murine samples: GFP-A 59-ACTACAACAGCCA-
CAACGTCTATATCA and GFP-B 59-GGCGGATCTTGAAG-
TTCACC. We also performed control Q-RT-PCR on the
Myosin-4 (MYH4) target gene expressed in the muscle but not
in the liver, and on the Albumin (ALB1) gene displaying the
opposite pattern. The following primers and probes were used for
the MYH4 mRNA quantification: forward primer 59-GAGG-
TTGCTCATCGGTTT, reverse primer 59-ATGGACACTGCT-
GAAGATAC, probe 59-FAM-GGCTTGGTGCTGGTTGCT-
TAMRA and for the ALB1 mRNA quantification: forward primer
59-GAGGTTGCTCATCGGTTT, reverse primer 59-ATGGAC-
ACTGCTGAAGATAC, probe 59-FAM-GGCTTGGTGCTG-
GTTGCT-TAMRA. All Q-RT-PCR were conducted using an
ABI StepOne Plus machine (Applied Biosystems) with TaqMan
chemistry, at the exception of GFP and mouse HPRT mRNA
amplification that were performed using SYBR Green chemistry.
The TaqMan PCR were done using the following program: initial
denaturation at 95uC for 20 s followed by 45 cycles of 3 s at 95uC
and 30 s at 62uC. The SYBR Green amplifications were
performed as followed: initial denaturation at 95uC for 20 s
followed by 40 cycles of 3 s at 95uC and 30 s at 60uC. Q-RT-PCR
data were normalized to the stably expressed HPRT mRNA for
NHP samples [36,37]. For murine samples, 11 potential reference
genes were evaluated using the Mouse Endogenous Control Gene
Panel kit (Tataa biocenter). The HPRT reference gene was
determined after Genex standard software (Tataa biocenter)
analysis as to be the most constantly expressed gene in mouse
muscle and liver. Thus, for both species, the Ct results obtained for
the transgene were normalized to the HPRT mRNA correspond-
ing values using the equation RQ=2
2(Ct target – Ct reference).
Generation of unmethylated and fully methylated
controls
The unmethylated version of the RSVp sequence was generated
by PCR amplification of the pZA-RSV-LEA29Y-WPRE-pA
vector plasmid using the pRSV F/pRSV R primer set (Table 1).
The fully methylated version of the RSVp was generated from the
previous control by in vitro methylation using M.Sss1 CpG
methyltransferase (New England Biolabs) according to the
manufacturer’s instructions for high density CpG DNA.
Sodium bisulfite conversion and low-throughput
pyrosequencing (LTS)
The optimal amount of 500 ng of total DNA extracted from
transduced NHP tissues was submitted to a sodium bisulfite
treatment using the EZ DNA Methylation-Gold kit (Zymo
research). In parallel, 10 ng of unmethylated or fully methylated
control were mixed with 500 ng of total DNA extracted from
naı ¨ve NHP skeletal muscle or liver and submitted to the same
treatment. The Pyro1 and Pyro2 CpG-rich regions of the RSVp
were then amplified by PCR using the following program: 5 min
at 95uC followed by 50 cycles of 20 s at 95uC, 30 s at 58uC (Pyro1)
or 52uC (Pyro2) and 15 s at 72uC. Each reaction was performed in
a final volume of 50 ml containing 10 ng of bisulfite converted
DNA, 2.5 U of Amplitaq Gold DNA polymerase (Applied
Biosystems), 5 mlo f1 0 6Amplitaq buffer, 0.2 mM of the forward
primer, 0.2 mM of the 59biotinylated reverse primer (Table 1),
800 mM of dNTP mix and 4 mM (Pyro1) or 8 mM (Pyro2) of
MgCl2. PCR products were purified with streptavidin coated
Sepharose HP beads (Amersham Biosciences) and the Vacuum
Prep Tool (Qiagen). Pyrosequencing was performed on the
PSQ96MA instrument (Qiagen) using PyroMark Gold Q96
Reagents (Qiagen). Sequencing primers were designed on the
upper strand of the rAAV and are listed in Table 2. Data were
acquired and analyzed with PyroQ-CpG software 2.0 (Qiagen).
Analysis was considered as ‘‘passed’’ if the non-CpG cytosines
internal controls were completely converted in T.
454 high-throughput sequencing (HTS)
Sodium bisulfite converted products were amplified by a two-
step methylation-independent PCR reaction in order to introduce
sample specific adapters used for the HTS workflow reaction
(454/Roche, Branford, CT). The first PCR step included 30 cycles
of amplification with the conventional primers (Table 1) that were
used previously to amplify Pyro1 and Pyro2 regions after bisulfite
conversion. The second step incorporated HTS primers (Table S1)
to create Titanium amplicon libraries. The composite HTS
primers contained the 454 primer A (forward) or B (reverse)
sequence, a MID (multiplex identifier) bar code which allowed
sample multiplexing, and the previously used LTS primer
sequence (Table 1). The annealing temperature was increased
after each cycle by +2uC until it reached the fusion primer Tm
(66uC). PCR products were examined by agarose gel electropho-
resis to ensure product amplification of the expected size with no
Table 1. PCR primers used for RSVp methylation analysis.
Primers Primer sequence Target Amplicon size (bp)
pRSV F 59-GTGTTGGAGGTCGCTGAGTAGT RSVp 749
pRSV R 59-CAGACTGAGCAGCGTCCTCT
pRSV Pyro1F 59-TGTATGAAGAATTTGTTTAGGGTTAG Pyro1 after bisulfite conversion 188
pRSV Pyro1R Biot 59-[Btn]-ATAAAACTACATTTCCCCCTCC
pRSV Pyro2F 59-TGTTTTATAAGGAGAGAAAAAGTAT Pyro2 after bisulfite conversion 224
pRSV Pyro2R Biot 59-[Btn]-TGTTTTATAAGGAGAGAAAAAGTAT
doi:10.1371/journal.pone.0020881.t001
Table 2. Sequencing primers used for low-throughput
sequencing.
Primers Primer sequence Target
Pyro1 Seq A 59-GAAGAATTTGTTTAGGGTT Pyro1 after bisulfite conversion
Pyro1 Seq B 59-GGGGATTAGGGTGTG
Pyro2 Seq A 59-TTTTATAAGGAGAGAAAAAG Pyro2 after bisulfite conversion
Pyro2 Seq B 59-GGTTTGATATGGATTGGA
doi:10.1371/journal.pone.0020881.t002
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Bioanalyzer (Santa Clara, CA). Barcoded samples were pooled
and run in duplicate in separate regions of a picotiter plate using
Titanium reagents on a Genome Sequencer FLX system (Roche,
Indianapolis, IN) according to standard procedures (Roche/454
Technical Bulletin TCB 005-2009). Sequencing reads containing
individual barcodes were identified and sorted using the Amplicon
Variant Analyzer Software (454, Branford, CT). The Genome
Sequencer Reference Mapper (gsMapper, Roche) program was
used to align reads to the reference sequences and was run using
default parameters except that all reads were treated individually.
‘‘High confidence’’ data were extracted using the following
Figure 1. Pyrosequencing assay for the Rous Sarcoma Virus promoter (RSVp) and transcription factor binding sites. (A) Schematic
representation of the rAAV-RSV-LEA29Y-WPRE-pA genome. The LEA29Y reporter gene sequence was cloned upstream of the Rous sarcoma virus
(RSV) promoter and downstream of the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). (B) Two high-density CpGs plots
were identified in the RSVp, named Pyro1 and Pyro2 (black boxes). CpG positions are marked by black vertical lines and numbered from 1 to 13 for
the 1
st CpG-rich region, Pyro1, and from 1 to 9 to the 2
nd region, Pyro2. PCR primers used to specifically amplify bisulfite-converted rAAV vector DNA
are represented as small open arrows. Reverse primers are 59-biotinylated allowing specific capture and subsequent purification of the PCR product.
Pyrosequencing allowed examination of 22 of 23 CpGs from the RSVp using the 4 sequencing primers represented as small black arrows. (C)
Transcription factor binding sites positions along the RSVp. (a) TF binding sites described by Mobley et al. [53]. (b) TF binding sites predicted by in
silico analysis using EMBOSS TFscan (http://mobyle.pasteur.fr).
doi:10.1371/journal.pone.0020881.g001
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was observed in forward and reverse reads and the read length was
at least 135 and 160 bp for Pyro1 and 2, respectively. Finally,
individual CpG were viewed in alignments of HTS reads using
the Integrated Genomics Viewer (http://www.broadinstitute.org/
igv/, Broad Institute, Cambridge, MA).
Statistical analysis of pyrosequencing results (LTS and
HTS)
Since we had to compare values on 22 CpGs, we used a non-
parametric statistical hypothesis test: the Mann-Withney U Test.
We considered that methylation level was significant above the
sensitivity threshold determined using unmethylated control, if p
value is under 0.001. Analyses were performed using GraphPad
PRISM 5.
Results
RSV promoter in the rAAV virions is not methylated
The rAAV vector expression cassette used here encodes the
LEA29Y molecule under the control of the RSVp (Fig. 1a). We
focused our investigation on the RSV promoter since CpG hyper-
methylation of promoters has been shown to be critical for
repression of transcription [15]. DNA methylation analyses were
conducted after sodium bisulfite treatment of DNA samples. The
bisulfite treatment and the subsequent RSVp-targeting PCR step
convert unmethylated C into T, whereas the methylated C remains
unmodified. Finally, the methylation percentage on each CpG in
the population was measured by low-throughput pyrosequencing
(LTS) based on the C/T ratio quantification. Two CpG-rich
regions named Pyro1 and Pyro2 were identified in the RSVp by
EMBOSS CpG plot (Fig. 1b) and two primers sets were designed to
analyze 22 of the 23 CpGs of these two regions (Fig. 1b).
The LTS assay was validated by generating an unmethylated
RSVp amplicon by PCR and a fully methylated fragment by
subsequent M.Sss1 in vitro methylation. Both controls were spiked
into NHP gDNA and the bisulfite-treated products were amplified
by PCR with the same efficiency, indicating that no amplification
bias existed in favor of one of the two targets (data not shown). The
CpG methylation median was determined by LTS for the
unmetylated control and was equal to 0.00% (DQ1-0.00;
DQ3+1.21) and 0.00% (DQ1-0.00; DQ3+1.24) for Pyro1 and
Pyro2 plots, respectively (Fig. 2a). The sensitivity threshold of the
assay is 1.87% since 90% of the values obtained for Pyro1 and
Pyro2 were lower. The medians obtained for the fully methylated
control were 91.23% (20.85; +3.87) and 97.30% (25.69; +1.97)
for Pyro1 and Pyro2 regions (Fig. 2b).
In order to assess the potential de novo DNA methylation after
vector administration, we measured the baseline methylation
status of the RSVp in the purified rAAV vector virions produced
in 293 cells [38]. Viral DNA was extracted from particles and
treated with bisulfite prior to LTS. CpG methylation medians
were equal to 0.00% (20.00; +1.85) on Pyro1 and 1.44%
(20.09; +0.64) on Pyro2 (Fig. 2c). Since these values were below
the pyrosequencing sensitivity threshold, we concluded that vector
DNA present in the virions prior in vivo administration was
unmethylated.
The RSVp of rAAV genomes extracted from NHP skeletal
muscle and liver remains essentially unmethylated
To investigate the methylation status of the rAAV genome in
vivo, five NHP were injected intramuscularly (IM) (Mac 1, 2 and
9) or intravenously (IV) (Mac 10 and 11) with the ssAAV2/
1-RSV-LEA29Y-WPRE-pA vector. Each animal received a dose
of 5.10
12 vg/kg. The LEA29Y molecule was detected in the
serum of the animals at different time points as previously
published in Toromanoff et al. [2] for Mac 1 and Mac 2, and in
Penaud-Budloo et al. [4] for Mac 9. These animals displayed a
1.5 to 2-fold reduction in protein level from <3t o6m o n t h sp i ,
before expression reached steady state. The LEA29Y concen-
tration in the serum of the IV-injected animals (Mac 10 and 11)
was below the sensitivity threshold of the ELISA assay (data
not shown).
In order to assess the potential involvement of de novo DNA
methylation in repression of transgene expression, total DNA was
extracted from skeletal muscle and liver biopsies taken 1 to 37
months post-injection (pi) and analyzed by bisulfite LTS [26].
Independent of the time or the vector delivery route, the RSVp
remains unmethylated across the Pyro2 CpG-rich region both in
the skeletal muscle (Fig. 3a) and in the liver (Fig. 3b). On the
contrary, most of the samples exhibited a low (below 6%) but
significant methylation level on the Pyro1 plot (Fig. 3). No
particular CpG site in the Pyro1 sequence was observed as being
preferentially methylated (data not shown).
LTS technology provides a global assessment corresponding to
the overall degree of methylation of the population of rAAV
molecules. However, a small fraction of molecules could
potentially be highly methylated but may remain undetectable
when analyzing the population. In order to study individual
rAAV genomic sequences, high-throughput sequencing (HTS)
[39] that generated clonal sequences from individual rAAV
molecules was performed on the same primate samples. PCR
primers (Table S1) were designed to amplify the two main
CpG-rich regions and were composed of a 454 sequencing
primer, a unique barcode tag also called multiplex identifier
(MID) which allowed sample multiplexing, and the pRSV
Pyro1F, 1R, 2F or 2R primer sequence previously used in the
LTS assay (Fig. 1b). This HTS approach created clonal
sequencing reads that could be individually scored and counted.
Analysis of the unmethylated control by HTS resulted in Pyro1
and Pyro2 methylation percentages of 0.37% (DQ1-0.15;
DQ3+0.08) and 0.30% (DQ1-0.05; DQ3+0.31), respectively.
90% of the values were below 0.60% of methylation, hence,
the HTS assay sensitivity threshold was lower than for the LTS.
Results obtained for the fully methylated control were 93.31%
(23.74; +2.54) and 98.31% (20.72; +0.73) for Pyro1 and Pyro2,
respectively. Vector genomes extracted from rAAV particles gave
a value of 0.12% (20.05; +0.07) methylation for Pyro1 and
0.00% (20.00; +0.21) for Pyro2 (Fig. 4) confirming the
unmethylated nature of the RSVp in rAAV virions.
Figure 2. Pyrosequencing assay sensitivity and methylation status of rAAV DNA in virions. Samples were sequenced a minimum of 5
times by low-throughput sequencing and are represented on a box plot graph. CpG methylation percentages are displayed depending on the CpG
position: 1.1 to 1.13 for Pyro1 region and 2.1 to 2.9 for Pyro2 region of the RSVp. Median values are represented by black horizontal lines. Grey boxes
contain 50% of values and extreme values are delimited as error bars. (A) Unmethylated control generated by PCR amplification of the RSVp
sequence from the pZA-RSV-LEA29Y-WPRE-pA plasmid. (B) Methylated control obtained by M.Sss1 in vitro methylation of the unmethylated RSVp
amplicon. (C) Viral DNA in particles. Viral DNA was extracted from rAAV2/1-RSV-LEA29Y-WPRE particles.
doi:10.1371/journal.pone.0020881.g002
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anticipated average of 2000 clonal sequencing reads per sample.
The average yield obtained for Pyro1 and Pyro2 was 7720 reads
(from 809 to 12414) and 1000 reads (from 221 to 3138),
respectively. The yield variation observed between Pyro1 and
Pyro2 could be explained, in part, by differences in the amplicon
length [28] (Table 1). Despite the high depth of sequencing read
coverage, no significant DNA methylation was detected by HTS
at the 22 CpG positions of the RSVp either in the NHP skeletal
muscle (Fig. 4a) or in the liver (Fig. 4b) at early or late time
points. Compared to LTS, smaller standard deviations were
observed indicating a higher degree of reproducibility. Bioinfor-
matic analyses of individual sequences confirmed that rAAV
molecules were not methylated on the RSVp, except for Mac10
at 1 month pi in the liver (Fig. 4b) for which we detected 0.41%
of reads (3130 depth of coverage) methylated on all the CpGs of
the Pyro2 region. Such rare events could not be detected by LTS
confirming the usefulness of the complementary HTS approach.
In conclusion, we demonstrated that the RSVp was not
subjected to de novo DNA methylation after rAAV transduction
of NHP muscle and liver, up to 3 years following vector
administration.
Figure 3. CpG methylation percentage of the RSVp after rAAV administration in NHP determined by low-throughput sequencing.
NHP were injected IM (Mac 1, Mac 2, and Mac 9) or IV (Mac 10 and Mac 11) with the rAAV2/1-RSV-LEA29Y-WPRE-pA vector. Each animal received a
dose of 5.10
12 vg/kg. Total DNA was extracted from transduced skeletal muscle (A) and liver (B) and subjected to sodium bisulfite conversion and
subsequent PCR amplification. Each sample was read at least 4 times by PSQ96 pyrosequencing for the two CpG-rich plots Pyro1 and Pyro2. na: not
analyzable. (
***) p value,0.001.
doi:10.1371/journal.pone.0020881.g003
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in the liver compared to NHP skeletal muscle
We have previously shown that the rAAV-mediated expression
of the LEA29Y transgene under the RSVp transcriptional control
was stable for more than 2 years in IM injected primates (Mac 1, 2,
and 9) [4]. This is consistent with a vector copy number ranging
from 9 to 11.8 vector genomes per diploid genome (vg/dge) at 20
months pi at <1 cm from the injection site in the tibialis anterior
muscle. However, these primates also had a substantial number of
vector copies in the liver, from 0.2 to 3.4 vg/dge at 31 months pi.
Since LEA29Y is a secreted protein, we could not correlate the
methylation status of rAAV genomes with the local transgene
expression by assessing the protein level. Thus, we developed a
quantitative RT-PCR (Q-RT-PCR) assay to determine the vector
mRNA copy number in each transduced tissue (skeletal muscle
and liver). Vector mRNA relative quantities (RQ) were deter-
mined by normalizing Ct values to the HPRT internal reference
that is similarly expressed in different rhesus monkey tissues [36].
RQ was then reported as a ratio to the vector genome copy
number (i.e. RQ/vg) for each sample. Total RNA was extracted
from the 5 injected primates and Q-RT-PCR quantification gave
values ranging from 0.02 to 1.98 RQ/vg in the liver and from
104.51 to 2355.48 RQ/vg in the muscle samples more than 1 year
after injection. Results obtained for Mac 9 are represented on
Figure 5 where the RQ/vg ratio was 1480 fold higher in the
muscle than in the liver at the later time point (37 months pi). As
controls, Q-RT-PCR analysis was performed on macaque
Myosin-4 (MYH4) and Albumin (ALB1) mRNA samples obtained
from Mac 9. We confirmed that these genes were specifically
Figure 4. CpG methylation percentage of the RSVp after rAAV administration in NHP determined by high-throughput sequencing.
NHP were injected IM (Mac 1, Mac 2, and Mac 9) or IV (Mac 10 and Mac 11) with the rAAV2/1-RSV-LEA29Y-WPRE-pA vector. Each animal received a
dose of 5.10
12 vg/kg. Total DNA was extracted from transduced skeletal muscle (A) and liver (B) and subjected to a sodium bisulfite conversion and
subsequent PCR amplification. 454 sequencing was performed to evaluate the Pyro1- and Pyro2-region methylation. (a) Bioinformatic analysis of this
sample revealed some sequences for which all the CpGs were methylated. (
***) p value,0.001.
doi:10.1371/journal.pone.0020881.g004
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MYH4 mRNA undetectable in the liver and the RQ values
ranged from 13.4 to 191.4 per copy of MYH4 gene in the muscle.
Inversely, RQ per ALB1 copy was equal to 0.23+/20.38 on
average in Mac 9 muscle and ranged from 1293.3 to 1940.8 in the
liver. In conclusion, the rAAV delivered RSVp was much more
efficient for driving transgene expression in NHP muscle
compared to the liver. Considering that most of the vector
genomes were detected in the muscle and the liver after IM
administration of rAAV vectors (Le Guiner et al., unpublished
data), the majority of the LEA29Y protein expression derives from
the injected skeletal muscle.
Since no DNA methylation was found in the RSVp either in the
skeletal muscle or in the liver, our data demonstrate that the
partial decrease of transgene expression during Phase 2 is not due
to DNA methylation and suggests the involvement of other
regulatory mechanisms.
Discussion
In the study presented here, we assessed the involvement of
DNA methylation in the partial repression of transgene expression
after rAAV vector administration in NHP skeletal muscle. In this
clinically relevant model, low-throughput pyrosequencing (LTS)
[26] and high-throughput 454 sequencing (HTS) [39] demon-
strated that the RSVp is not subject to de novo CpG methylation at
early or late time points in NHP muscle and liver. When the
population or individual rAAV molecules are analyzed by
pyrosequencing, no methylation was seen. Thus, the reduction
in protein levels observed in Phase 2 is not due to the methylation
of a portion of the rAAV genome population. Other mechanisms
are likely involved such as the loss of some rAAV forms or
deletions/rearrangements that are known to occur during rAAV
genome circularization and concatemerization. Sun et al. recently
suggested that recombination of ITR and adjacent regions after
transduction of NHP liver may impact the integrity of the
transgene cassette, particularly in the promoter due to its close
proximity to the ITR [10].
Pyrosequencing is a recent technology that enables the
evaluation of the DNA methylation percentage for each CpG
position in a population of molecules converted by sodium bisulfite
and amplified using PCR [26,27]. It circumvents the poor
sensitivity and the biases associated with classical sub-cloning
and Sanger sequencing approaches [25]. In our assay, the in vitro
methylated control appeared to be 96.25% methylated overall
which was satisfactory considering the under-estimation of high
levels of methylation using pyrosequencing technology [25], and
incomplete enzymatic methylation by M.Sss1 methyltransferase
[40]. We demonstrated that no methylation was detectable in the
promoter region of the packaged rAAV genomes. Since CpGs of
rAAV genomes are unmethylated in virions, this could increase
the susceptibility to TLR9 recognition in the endosomes and
promote AAV-targeted adaptive immune responses [24,41].
Indeed, Zhu et al. demonstrated that the TLR9-MyD88 pathway
was involved in the activation of CD8+ T cell responses to both
the transgene product and the rAAV2 capsid, leading to loss of
transgene expression [42].
In order to evaluate the potential de novo methylation in vivo,t h e
percentage of DNA methylation was measured along the RSVp
from 1 month to 37 months after rAAV2/1 administration in NHP.
Some liver samples (indicated as ‘‘na’’ on Fig. 3b) could not be
analyzed by LTS probably because mutations/rearrangements
could have occurred in the RSVp sequence during circularization
and concatemerization of rAAV genomes [10]. By providing
resolution of individual CpG, LTS allowed visualization of
methylation variation between CpG positions in the population.
The Pyro1 region was found in the first instance slightly methylated
for most of the samples, while Pyro2 remained unmethylated.
Interestingly, most transcription factor (TF) binding sites are located
in the Pyro2 region (Fig. 1c); and this region has been described as
indispensable for RSVp-driven transcription [43]. In order to
confirm these results, we chose to perform high-throughput
Figure 5. Differential transgene expression level in Mac 9 skeletal muscle and liver. mRNA relative quantities (RQ) were determined at the
indicated time points by quantitative RT-PCR using WPRE as target rAAV sequence and HPRT as endogenous macaque reference, and the equation
relating these: RQ=2
2(Ct WPRE – Ct HPRT). Data are expressed relative to the vector genome copy number (vg) determined by Q-PCR using LEA29Y as
target and e-globin macaque gene as endogenous.
doi:10.1371/journal.pone.0020881.g005
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allows the simultaneous analysis of 400,000 individual molecules on
a single picotiter plate with a single-read sequence error of less than
0.5% [39,28]. Moreover, HTS provided additional information
concerning the distribution of the CpG methylation in the
population of rAAV genomes. Contrary to the LTS results, no
significant DNA methylation of the RSVp was detected by HTS.
Since HTS generates individual clonal sequence reads, incomplete
bisulfite converted sequences that can cause rare false positives
could be identified based upon assessment of non-CpG cytosines.
These false positives sequence reads appeared to be shorter than the
expected sequence and thus were removed using optimized cut-offs
applied during bioinformatic analysis. This additional selective filter
could explain the lower threshold observed in HTS compared to
LTS (1.87% and 0.60%, respectively) as well as the higher
reproducibility. Overall, the methylation levels obtained by LTS
and HTS were similar considering the described technical
variability, due in part to errors known to occur in homopolymeric
nucleotides stretches [28].
One cannot exclude that the RSV promoter per se is responsible
for the resistance of the rAAV DNA to methylation since it is
known as a strong constitutive promoter [44]. However, several in
vitro studies demonstrated that the partial or complete CpG
methylation of the RSVp prior to transfection could severely alter
the transgene transcription level [32,33,45,46]. The plasmid used
in these studies contained an EBNA1/OriP sequence that
conferred plasmid chromosome attachment and maintenance
during cell division [12]. In fact, the RSVp was found to be
susceptible to de novo methylation only when integrated, in clones
generated by plasmid transfection with antibiotic selection [47].
Since rAAV vectors are maintained nearly exclusively as episomes
in skeletal muscle [4,48] and liver [10,11], silencing due to
integration into heterochromatin should not contribute signifi-
cantly to repressing rAAV-mediated transgene expression. Thus,
with the exception of a single sample (Mac 10 liver at 1 month pi),
the rAAV integration frequency was likely too low in our primate
samples to detect DNA methylation associated with such silencing.
Indeed, we failed to detect any integration event by LAM-PCR
(linear amplification-mediated PCR) in Mac 1, Mac 2 and Mac 9
injected muscles [4]. Furthermore, it has been recently demon-
strated that the silencing of transgene expression in mouse liver by
plasmid bacterial backbone DNA was consistent with the histone
modifications profile but was independent of CpG methylation
[22,23]. Similarly, naked plasmid was recently shown to be
unmethylated along the hAAT promoter after hydrodynamic
liver-directed delivery in mice, which was consistent with a stable
FIX transgene expression for 3 months [49]. We hypothesized
that, like plasmid DNA, the episomal status of rAAV could result
in the absence of de novo DNA methylation in these quiescent
tissues.
Finally, we demonstrated by Q-RT-PCR that the RSVp was
highly active in NHP skeletal muscle but restricted in the liver after
ssAAV2/1 vector administration. This was consistent with Salva et
al. data obtained in mice after single-stranded AAV6 injection
[50]. They showed that the alkaline phosphatase (AP) reporter
protein was poorly expressed in the liver while it was highly
expressed in many other organs, including the skeletal muscle, 1
month after rAAV-RSV-AP IV injection. The constitutive CMV
promoter was also shown to drive a 10-fold greater AP activity
than the RSVp in the liver [50]. Similar, we observed a much
higher RSV-driven transgene expression in the skeletal muscle of
mice that were injected IM with a ssAAV2/8-RSV-GFP vector,
compared to the liver (data not shown). In conclusion, the RSVp
used in a context of ssAAV is a suitable promoter to drive
expression in skeletal muscle, but a very weak promoter in NHP
and murine liver.
Since this study was carried out in normal quiescent tissues,
DNA methylation inheritance mechanisms that occur during
DNA replication and involve the DNA methyltransferase 1
(Dnmt1) are not expected to play a role. However, other DNA
methyltransferases, Dnmt3a and 3b, also called de novo DNA
methyltransferases, are expressed in the skeletal muscle and the
liver and are capable of methylating single- or double-stranded
unmethylated DNA [51]. Whereas global differential methylation
is a well-described mechanism occurring during embryonic
development [52], the extent and the role of de novo methylation
in adult quiescent tissues remain unclear. Thus, it could be
interesting to monitor DNA methylation and, more generally,
additional epigenetic modifications in a regenerative cellular
context such as dystrophic muscle, to correlate the potential
impact on vector-derived transgene expression.
Supporting Information
Table S1 PCR primers used for high-throughput 454
sequencing analysis. Underlined sequences correspond to 454-
bead attachment sequence (A or B). Sequences in bold correspond
to the tags or Multiplex identifier (MID) sequences and in normal
font to the target-specific sequences.
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